```
     FILE 'REGISTRY' ENTERED AT 23:39:05 ON 08 AUG 2004

     FILE 'REGISTRY' ENTERED AT 23:39:08 ON 08 AUG 2004
L1                STRUCTURE UPLOADED
L2             50 S L1 SSS SAM
L3          35447 S L1 SSS FULL

     FILE 'STNGUIDE' ENTERED AT 23:39:48 ON 08 AUG 2004

     FILE 'REGISTRY' ENTERED AT 23:40:29 ON 08 AUG 2004
L4                STRUCTURE UPLOADED
L5             11 S L4 SSS SAM
L6           2415 S L4 SSS FULL

     FILE 'STNGUIDE' ENTERED AT 23:41:07 ON 08 AUG 2004

     FILE 'REGISTRY' ENTERED AT 23:41:56 ON 08 AUG 2004
L7                STRUCTURE UPLOADED
L8             20 S L7 SSS SAM
L9           2794 S L7 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 23:42:31 ON 08 AUG 2004
L10           294 S (L3 OR L6 OR L9) AND (CANCER? OR NEOPLAS? OR ADENOCARCINOM? O
L11           197 S L10 AND PY<=2001

     FILE 'STNGUIDE' ENTERED AT 23:47:04 ON 08 AUG 2004

     FILE 'HCAPLUS' ENTERED AT 23:47:27 ON 08 AUG 2004

     FILE 'STNGUIDE' ENTERED AT 23:47:54 ON 08 AUG 2004

     FILE 'REGISTRY' ENTERED AT 23:50:46 ON 08 AUG 2004
L12             1 S 100-33-4/RN

     FILE 'HCAPLUS' ENTERED AT 23:51:08 ON 08 AUG 2004
L13            61 S L12 AND (CANCER? OR NEOPLAS? OR ADENOCARCINOM? OR SARCOM? OR
L14            35 S L13 AND PY<=2001
```

```
=> d his

     (FILE 'HOME' ENTERED AT 00:28:05 ON 09 AUG 2004)

     FILE 'REGISTRY' ENTERED AT 00:28:21 ON 09 AUG 2004
L1              STRUCTURE UPLOADED
L2            50 S L1 SSS SAM
L3          3553 S L1 SSS FULL

     FILE 'HCAPLUS, USPATFULL' ENTERED AT 00:29:22 ON 09 AUG 2004
L4           479 S L3 AND (CANCER? OR NEOPLAS? OR LYMPHOM? OR LEUKEMI? OR CARCIN
L5           454 DUP REM L4 (25 DUPLICATES REMOVED)
L6           255 S L5 AND PY<=2001
L7             5 S L6 AND PENTAMIDIN?

     FILE 'STNGUIDE' ENTERED AT 00:37:20 ON 09 AUG 2004

     FILE 'USPATFULL' ENTERED AT 00:38:10 ON 09 AUG 2004
L8           195 S L3 AND (CANCER? OR NEOPLAS? OR LYMPHOM? OR CARCINOMA? OR SARC
L9            82 S L8 AND PY<=2001

     FILE 'STNGUIDE' ENTERED AT 00:40:01 ON 09 AUG 2004

     FILE 'USPATFULL' ENTERED AT 00:41:35 ON 09 AUG 2004
L10          185 S L3 AND (CANCER? OR LYMPHOM? OR CARCINOMA? OR SARCOMA? OR ADEN
L11           75 S L10 AND PY<=2001
L12            0 S L11 NOT L9
L13            7 S L9 NOT L11
```

```
=> e albendazole/cn
E1            1      ALBEMET 562/CN
E2            1      ALBEMET-150/CN
E3            1 --> ALBENDAZOLE/CN
E4            1      ALBENDAZOLE NITRATE/CN
E5            1      ALBENDAZOLE OXIDE/CN
E6            1      ALBENDAZOLE SULFONE/CN
E7            1      ALBENDAZOLE SULFOXIDASE/CN
E8            1      ALBENDAZOLE SULFOXIDE/CN
E9            1      ALBENDAZOLE-B-CYCLODEXTRIN COMPLEX (1:1)/CN
E10           1      ALBENDAZOLE-2-AMINOSULFONE/CN
E11           1      ALBENE/CN
E12           1      ALBENONE/CN

=> s e3
L14           1 ALBENDAZOLE/CN

=> d l14

L14  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   54965-21-8  REGISTRY
CN   Carbamic acid, [5-(propylthio)-1H-benzimidazol-2-yl]-, methyl ester (9CI)
     (CA INDEX NAME)
OTHER NAMES:
CN   Albamelin
CN   Albendazole
CN   Albenza
CN   Alzental
CN   Methyl 5-propylthio-2-benzimidazolecarbamate
CN   NSC 220008
CN   SKF 62979
CN   Valbazen
CN   Vermitan
CN   Zentel
FS   3D CONCORD
MF   C12 H15 N3 O2 S
CI   COM
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*,
       BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT,
       CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU,
       EMBASE, IFICDB, IFIPAT, IFIUDB, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH,
       IPA, MEDLINE, MRCK*, NIOSHTIC, PHAR, PROMT, PROUSDDR, RTECS*, SYNTHLINE,
       TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU
         (*File contains numerically searchable property data)
     Other Sources:   EINECS**, WHO
         (**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA  CAplus document type:  Book; Conference; Dissertation; Journal; Patent
RL.P   Roles from patents:  ANST (Analytical study); BIOL (Biological study);
       PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or
       reagent); USES (Uses)
RLD.P  Roles for non-specific derivatives from patents:  BIOL (Biological
       study); PROC (Process); USES (Uses)
RL.NP  Roles from non-patents:  ANST (Analytical study); BIOL (Biological
       study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP
       (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or
       reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents:  ANST (Analytical
       study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU
       (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); USES
       (Uses)
```



```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

             943 REFERENCES IN FILE CA (1907 TO DATE)
              27 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
             944 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> s e8 and e6
             1 "ALBENDAZOLE SULFOXIDE"/CN
             1 "ALBENDAZOLE SULFONE"/CN
L15          0 "ALBENDAZOLE SULFOXIDE"/CN AND "ALBENDAZOLE SULFONE"/CN

=> s (e6 or e8
UNMATCHED LEFT PARENTHESIS '("ALBENDAZO'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s (e6 or e8)
             1 "ALBENDAZOLE SULFONE"/CN
             1 "ALBENDAZOLE SULFOXIDE"/CN
L16          2 ("ALBENDAZOLE SULFONE"/CN OR "ALBENDAZOLE SULFOXIDE"/CN)

=> d l16 1 2

L16  ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   75184-71-3  REGISTRY
CN   Carbamic acid, [5-(propylsulfonyl)-1H-benzimidazol-2-yl]-, methyl ester
     (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   Albendazole sulfone
FS   3D CONCORD
DR   76567-28-7
MF   C12 H15 N3 O4 S
LC   STN Files:   AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA,
       CAPLUS, CHEMCATS, DDFU, DRUGU, EMBASE, IPA, MEDLINE, RTECS*, TOXCENTER,
       USPAT2, USPATFULL, VETU
         (*File contains numerically searchable property data)
DT.CA  CAplus document type:  Conference; Journal; Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP (Preparation); USES
       (Uses)
RL.NP  Roles from non-patents:  ANST (Analytical study); BIOL (Biological
       study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP
       (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or
       reagent); USES (Uses)
```



```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

              144 REFERENCES IN FILE CA (1907 TO DATE)
              144 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16  ANSWER 2 OF 2  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   54029-12-8  REGISTRY
CN   Carbamic acid, [5-(propylsulfinyl)-1H-benzimidazol-2-yl]-, methyl ester
     (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   (±)-Albendazole sulfoxide
CN   Albendazole oxide
CN   Albendazole sulfoxide
CN   Ricobendazole
CN   RS 8852
CN   Rycobendazole
FS   3D CONCORD
DR   122063-18-7
MF   C12 H15 N3 O3 S
CI   COM
LC   STN Files:   AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
       BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CHEMCATS, CSCHEM, DDFU,
       DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, PHAR,
       TOXCENTER, USAN, USPATFULL, VETU
         (*File contains numerically searchable property data)
     Other Sources:   WHO
DT.CA  CAplus document type:  Conference; Dissertation; Journal; Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP (Preparation); PROC
       (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.P  Roles for non-specific derivatives from patents:  BIOL (Biological
       study); USES (Uses)
RL.NP  Roles from non-patents:  ANST (Analytical study); BIOL (Biological
       study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP
       (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or
       reagent); USES (Uses)
```



```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**
```

```
272 REFERENCES IN FILE CA (1907 TO DATE)
  3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
272 REFERENCES IN FILE CAPLUS (1907 TO DATE)
```

L14 ANSWER 20 OF 35 HCAPLUS COPYRIGHT 2004 ACS on STN

AB In the present paper, the authors present data showing that the effect of the binding of the antitumor drug Pt-pentamidine to nucleosomal DNA is the opposite to that of the cis-DDP compound, since it causes strong stabilization of the double helix to heat denaturation and because in nucleosome-Pt-pentamidine complexes, the nucleosomal denatured DNA is able to reassoc. at 71°C. Upon binding, the pentamidine ligand, by itself, also produces stabilization of the nucleosomal DNA, but the effect is lower than that induced by Pt-pentamidine. It seems that in Pt-pentamidine-nucleosome complexes, about 50% of the adducts are formed during the first hour of incubation of the nucleosomes with the drug, since the increase in Tm of the DNA of these complexes is 53% of the total increase in Tm of the DNA of the Pt-pentamidine-nucleosome complexes formed in 48 h. The 'in vitro' screening of the antiproliferative activity of Pt-pentamidine against 60 tumor cell lines indicated that this antitumor compound shows higher antiproliferative activity against small cell lung, non-small cell lung and melanoma **cancer** lines than against the rest of the cell lines.

ACCESSION NUMBER:	1994:45376 HCAPLUS
DOCUMENT NUMBER:	120:45376
TITLE:	Binding of platinum-pentamidine to nucleosomal DNA. Studies of the antiproliferative activity of the drug against human **cancer** cells
AUTHOR(S):	Perez, J. M.; Requena, J. M.; Craciunescu, D.; Doadrio, J. C.; Alonso, C.
CORPORATE SOURCE:	Fac. Cienc., Univ. Auton. Madrid, Madrid, 28049, Spain
SOURCE:	Chemico-Biological Interactions (**1993**), 89(1), 61-72 CODEN: CBINA8; ISSN: 0009-2797
DOCUMENT TYPE:	Journal
LANGUAGE:	English

TI Binding of platinum-pentamidine to nucleosomal DNA. Studies of the antiproliferative activity of the drug against human **cancer** cells

SO Chemico-Biological Interactions (**1993**), 89(1), 61-72
CODEN: CBINA8; ISSN: 0009-2797

AB . . . cell lines indicated that this antitumor compound shows higher antiproliferative activity against small cell lung, non-small cell lung and melanoma **cancer** lines than against the rest of the cell lines.

IT **Neoplasm** inhibitors
(platinum-pentamidine as, against human cells, binding to nucleosomal DNA in relation to)

IT **100-33-4D**, Pentamidine, platinum complexes 7440-06-4D, Platinum, complexes with pentamidine, biological studies
RL: BIOL (Biological study)
(antitumor activity against human cells and binding to nucleosomal DNA of)

IT **100-33-4D**, Pentamidine, platinum complexes
RL: BIOL (Biological study)
(antitumor activity against human cells and binding to nucleosomal DNA of)

RN 100-33-4 HCAPLUS

CN Benzenecarboximidamide, 4,4'-[1,5-pentanediylbis(oxy)]bis- (9CI) (CA INDEX NAME)

10/677,664



DELACROIX